Are you Dr. Mohan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 101 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-322-3000Fax+1 615-936-1812
Summary
- Dr. Sanjay Mohan, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee, Alabama, and Ohio. He is affiliated with Vanderbilt University Medical Center and is an Assistant Professor at Vanderbilt University School of Medicine.
Education & Training
- Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2008 - 2011
- Cleveland Clinic FoundationResidency, Internal Medicine, 2004 - 2007
- Pennsylvania State University College of MedicineClass of 2004
Certifications & Licensure
- TN State Medical License 2011 - 2026
- AL State Medical License 2020 - 2020
- OH State Medical License 2004 - 2011
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Publications & Presentations
PubMed
- 39 citationsMyeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.Aaron T Gerds, Jason Gotlib, Haris Ali, Prithviraj Bose, Andrew Dunbar
Journal of the National Comprehensive Cancer Network. 2022-09-01 - 26 citationsPredictive factors for latency period and a prognostic model for survival in patients with therapy‐related acute myeloid leukemiaMoshe Chaim Ornstein, Sudipto Mukherjee, Sanjay R. Mohan, Paul Elson, Ramon V. Tiu
American Journal of Hematology. 2014-02-01 - 6 citationsA randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, John M Pagel, Jerald P Radich
Leukemia. 2024-01-01